Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
MRNA
SELLModerna, Inc. · Healthcare · United States · $21.5B · Avg Vol: $470M/d
COMPANY DESCRIPTION
Moderna, Inc. is a biotechnology company focused on messenger RNA (mRNA) therapeutics and vaccines for infectious diseases, immuno-oncology, and rare diseases. Its pioneering mRNA technology platform, broad pipeline, and demonstrated ability to rapidly develop vaccines constitute its competitive moat. Moderna is a leading innovator in mRNA technology, distinguished by its rapid drug development capabilities and extensive investment in R&D.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 18.9B | 6.8B | 3.2B | 1.9B | -53.3% | 2.2B | 2.1B | 2.5B | 14.6% |
| EPS | 30.31 | 21.26 | -12.33 | -9.28 | -7.26 | -29.9% | -7.83 | -8.66 | -4.75 | — |
| Shares | — | 385.0M | 382.0M | 386.0M | 394.0M | +2.3% | 396.8M | — | — | — |
| Debt | — | 1.2B | 1.2B | 747.0M | 1.3B | 2.8% | 1.3B | — | — | — |
| Equity | — | 19.1B | 13.9B | 10.9B | 8.7B | -23.2% | — | — | — | — |
| Op CF | — | 5.0B | -3.1B | -3.0B | -1.9B | — | -1.5B | — | — | — |
| Inv CF | — | -5.2B | 4.2B | 1.9B | 1.9B | — | — | — | — | — |
| Fin CF | — | -3.4B | -1.4B | 56.0M | 593.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MRNA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MRNA | Moderna, Inc.(you) | $21.5B | 29 | SELL |
| ALNY | Alnylam Pharmaceuticals, Inc. | $36.3B | 29 | SELL |
| BBIO | BridgeBio Pharma, Inc. | $16.5B | 37 | HOLD |
| NUVL | Nuvalent, Inc. | $9.8B | 30 | SELL |
| CYTK | Cytokinetics, Incorporated | $11.0B | 26 | SELL |
| RVMD | Revolution Medicines, Inc. | $40.2B | 25 | SELL |
| MDGL | Madrigal Pharmaceuticals, Inc. | $12.6B | 37 | HOLD |
| PRAX | Praxis Precision Medicines, Inc. | $9.1B | 28 | SELL |
| ARWR | Arrowhead Pharmaceuticals, Inc. | $12.1B | 36 | HOLD |
| CRNX | Crinetics Pharmaceuticals, Inc. | $8.9B | 30 | SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.7%